Modalis Therapeutics is a biotech company focused on the development of therapeutic drugs for genetic diseases using its proprietary genome editing platform, CRISPR-GNDM. With a mission to address gene-related diseases, Modalis Therapeutics aims to leverage the power of CRISPR technology to revolutionize the field of gene therapy. Their website provides information about their science, including gene therapy and CRISPR-GNDM.

Visitors can access details about the company's business model, development pipeline, and executive leadership. The website also offers a range of investor relations resources such as news, financial information, and an IR calendar. Additionally, Modalis Therapeutics highlights their commitment to sustainability.

With a strong focus on cutting-edge science and a dedication to improving patient outcomes, Modalis Therapeutics is poised to make significant advancements in the field of genetic medicine